Goldman Sachs Lowers Pfizer's Price Target Ahead of Earnings Report
Goldman Sachs has lowered its price target for Pfizer to $26, maintaining a 'hold' rating, as the company faces challenges including declining Covid sales, patent expirations, and uncertainty around its pipeline growth. The move comes ahead of Pfizer's first-quarter 2026 earnings report, which is expected to provide insight into the company's post-pandemic performance.
Tickers: $PFE
Topics: analyst rating earnings report pharmaceutical industry price target stock forecast